Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if reducing or eliminating a dopamine agonist (DA)
causing one of the side effects of daytime sleepiness, swelling of the lower legs or feet,
hallucinations or impulsive behaviors while adding orally disintegrating selegiline can
eliminate the adverse effect and maintain control of Parkinson's disease (PD) symptoms.
Phase:
Phase 4
Details
Lead Sponsor:
Parkinson's Disease and Movement Disorder Center of Boca Raton
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.